COMMUNIQUÉS West-GlobeNewswire

Ipsen to acquire Kartos Therapeutics, expanding hemato-oncology late-stage pipeline
29/06/2026
Acquisition adds navtemadlin, a late-stage rare blood cancer asset in Phase III. This hemato-oncology program in myelofibrosis expands Ipsen’s growing Oncology portfolio Navtemadlin, an oral MDM2 inhibitor, has the [...]
AB Science annonce l’achèvement de l’étape 3 de la phase 1, évaluant la combinaison d’AB8939 et du vénétoclax dans le traitement de la LMA réfractaire ou en rechute
29/06/2026
COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE L’ACHÈVEMENT DE L’ÉTAPE 3 DE LA PHASE 1, ÉVALUANT LA COMBINAISON D’AB8939 ET DU VÉNÉTOCLAX DANS LE TRAITEMENT DE LA LEUCÉMIE MYÉLOÏDE AIGUË RÉFRACTAIRE OU EN RECHUTE LA [...]
Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform
29/06/2026
AXELIOS 1 delivers a unique combination of accuracy, speed, scalability and cost efficiency, giving laboratories of all sizes the freedom to customise their workflows and explore a wider array of applications. Powered [...]
Ipsen acquiert Kartos Therapeutics et élargit son portefeuille d’hémato-oncologie à un stade avancé de développement
29/06/2026
Cette acquisition ajoute le navtemadlin, un candidat médicament de stade avancé contre un cancer rare du sang, actuellement en phase III de développement clinique. Ce programme d'hémato-oncologie, ciblant la [...]
Bavarian Nordic Receives Health Canada Approval for Chikungunya Vaccine
29/06/2026
COPENHAGEN, Denmark, June 29, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that Health Canada has approved VIMKUNYA ® (recombinant, adsorbed) for immunization to prevent disease caused by chikungunya virus [...]
AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML
29/06/2026
PRESS RELEASE AB SCIENCE REPORTS COMPLETION OF THE STEP 3 OF PHASE 1, EVALUATING THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA THE COMBINATION OF AB8939 [...]
BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia
28/06/2026
- Phase 3 PROPEL 3 data published today in NEJM were simultaneously presented at ICCBH in a late-breaking oral presentation; presentation includes new arm span Z-score data showing a statistically significant [...]
TBoostExperts.com Announces Availability of 2026 Consumer Report on Testosterone Booster Supplements and Men’s Health Supplement Evaluation
27/06/2026
New report provides an educational framework for reviewing testosterone booster supplements, ingredient transparency, supplement labels, consumer safety considerations, and responsible product research. NEW YORK,USA, [...]
BurnTide Official Announces 2026 In Across The USA, UK, CA and AU Effective Formula Burn Tide Gummies For Weight Loss in Markets
27/06/2026
Announcing BurnTide Gummies, a natural supplement designed to complement healthy weight loss. Learn how Burn Tide fits into a balanced diet, active lifestyle, and daily wellness routine. New York City, June 27, 2026 ( [...]
Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results
27/06/2026
LIKMEZ® (ATI-1501) commercial momentum building in U.S. market US$40 million NIAID award supporting VXV-01 advancement through Phase 1 HALIFAX, Nova Scotia, June 26, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. ( [...]
Nordic Naturals Ultimate Omega Featured in New Erewhon Smoothie by J Balvin
26/06/2026
Watsonville, CA, June 26, 2026 (GLOBE NEWSWIRE) -- Nordic Naturals , the #1 selling fish oil brand in the U.S.‡, today announced that its award-winning Ultimate Omega® is a featured ingredient in Erewhon's newly [...]
Universe Pharmaceuticals INC Announces Strategic Acquisition to Expand Pharmaceutical Patent Portfolio
26/06/2026
Ji'an, Jiangxi, China, June 26, 2026 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ: UPC) (“Universe Pharmaceuticals” or the “Company”), a pharmaceutical producer and distributor in China, today announced that [...]
Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia
26/06/2026
Webcast on Monday, June 29, 2026, at 7:45 am ET BALA CYNWYD, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing [...]
Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc
26/06/2026
Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination BURLINGTON, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) ( [...]
Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease
26/06/2026
WILMETTE, Ill., June 26, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with [...]
Crescent Biopharma Announces Grants of Inducement Awards
26/06/2026
WALTHAM, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma , Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies [...]
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance
26/06/2026
BEDMINSTER, N.J., June 26, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on June 24, 2026, it received a notice (the “Notice”) from the NYSE [...]
Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®
26/06/2026
COPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company has been added to the broad-market Russell 3000 ® Index, the large-cap Russell 1000 ® Index, the [...]
VitalHub Announces Results of Annual General Meeting of Shareholders
26/06/2026
TORONTO, June 26, 2026 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) announced today the voting results from its annual general meeting of shareholders held virtually on June [...]

Pages